This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers, Sanofi Lower Guidance

Bristol-Myers Squibb (BMY - Get Report) and marketing partner Sanofi (SNY - Get Report) warned Friday that their earnings this year will take big hits from sales of a generic version of their Plavix blood-thinning drug.

A federal judge Thursday ruled in the two companies' favor by ordering Apotex, the maker of generic Plavix, to halt sales. But the court didn't require Apotex to recall sales or shipments it has made since launching the generic on Aug. 8. Bristol-Myers and Sanofi said they¿re assuming plenty of damage has already been done.

Bristol-Myers said Friday evening that it now expects 2006 earnings of "no less" than 95 cents a share, about 20% less than its previous EPS forecast of $1.15 to $1.25. The company said it didn't know how much generic Plavix Apotex had sold but was assuming enough had hit the market to satisfy all U.S. demand this year.

Earlier Friday, Sanofi had warned that 2006 adjusted EPS would come in about 2% higher than last year's 4.74 euros, or $6.09. The company previously had forecast 12% growth.

Plavix accounted for $3.8 billion of Bristol's sales last year, or 20% of the total. France's Sanofi-Aventis collected sales of $2.45 billion from the drug, or 7.4% of its total revenue.

Thursday's ruling was a preliminary injunction aimed at preventing Apotex from selling more of its drug until a court can take up its patent challenge against Bristol-Myers and Sanofi in January.

Shares of Bristol-Myers ended Friday up $1.20, or 5.5%, at $22.95, buoyed by investor enthusiasm over the injunction. Sanofi ended the session up 42 cents, or 0.9%, at $45.37.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $71.96 0.00%
SNY $41.46 0.00%
AAPL $93.64 0.00%
FB $118.57 0.00%
GOOG $698.21 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs